

DAFTAR PUSTAKA

- Advisory, F. I. P. H. (2019) 'FIP HEALTH ADVISORY CORONAVIRUS 2019-nCoV OUTBREAK : Information and interim guidelines for pharmacists and the pharmacy workforce'.
- Boriskin, Y.S. *et al.* (2008) *Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion, Current Medicinal Chemistry.*
- BPOM (2020) *Pedoman Pelayanan Publik di Bidang Obat Dalam Kondisi Pandemi COVID-19.*
- Burhan, E. *et al.* (2020) *PEDOMAN TATALAKSANA COVID-19 Edisi 3 TIM EDITOR Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI).*
- Cai, Qingxian *et al.* (2020) "Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study," *Engineering* [Preprint]. doi:10.1016/j.eng.2020.03.007.
- Cao, B. *et al.* (2020) "A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19," *New England Journal of Medicine*, 382(19), pp. 1787–1799. doi:10.1056/NEJMoa2001282.
- Chen, Y., Liu, Q. and Guo, D. (2020) "Emerging coronaviruses: Genome structure, replication, and pathogenesis," *Journal of Medical Virology*. John Wiley and Sons Inc., pp. 418–423. doi:10.1002/jmv.25681.
- Cheng, F. *et al.* (2020) "Analysis of influencing factors and pharmaceutical care of patients with COVID-19 in Fangcang Shelter Hospital," *Infection and Drug Resistance*, 13, pp. 3443–3450. doi:10.2147/IDR.S263961.
- Damle, B. *et al.* (2020a) "Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19," *Clinical Pharmacology and Therapeutics*. Nature Publishing Group, pp. 201–211. doi:10.1002/cpt.1857.
- Damle, B. *et al.* (2020b) "Clinical Pharmacology Perspectives on the Antiviral

Activity of Azithromycin and Use in COVID-19,” *Clinical Pharmacology and Therapeutics*. Nature Publishing Group, pp. 201–211. doi:10.1002/cpt.1857.

Devaux, C.A. *et al.* (2020) “New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,” *International Journal of Antimicrobial Agents*, 55(5). doi:10.1016/j.ijantimicag.2020.105938.

van Doremalen, N. *et al.* (2020) “Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,” *New England Journal of Medicine*, 382(16), pp. 1564–1567. doi:10.1056/nejmc2004973.

Du, Y.X. and Chen, X.P. (2020) “Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection,” *Clinical Pharmacology and Therapeutics* [Preprint]. Nature Publishing Group. doi:10.1002/cpt.1844.

Fears, A.C. *et al.* (2020) “Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions,” *medRxiv: the preprint server for health sciences* [Preprint]. doi:10.1101/2020.04.13.20063784.

Fiorino, S. *et al.* (2020) “Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy,” *Aging Clinical and Experimental Research*. Springer Science and Business Media Deutschland GmbH, pp. 2115–2131. doi:10.1007/s40520-020-01669-y.

de Flora, S., Balansky, R. and la Maestra, S. (2020) “Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19,” *FASEB Journal*, 34(10), pp. 13185–13193. doi:10.1096/fj.202001807.

Fu, B., Xu, X. and Wei, H. (2020) “Why tocilizumab could be an effective treatment for severe COVID-19?,” *Journal of Translational Medicine*. BioMed Central Ltd. doi:10.1186/s12967-020-02339-3.

Geleris, J. *et al.* (2020) “Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,” *New England Journal of Medicine*, 382(25), pp. 2411–2418. doi:10.1056/nejmoa2012410.

Guan, W. *et al.* (2020) “Clinical Characteristics of Coronavirus Disease 2019 in China,” *New England Journal of Medicine*, 382(18), pp. 1708–1720.

doi:10.1056/nejmoa2002032.

Hung, I.F.N. *et al.* (2020) “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial,” *The Lancet*, 395(10238), pp. 1695–1704. doi:10.1016/S0140-6736(20)31042-4.

Johnson, R.M. and Vinetz, J.M. (2020) “Dexamethasone in the management of covid -19,” *The BMJ*. BMJ Publishing Group. doi:10.1136/bmj.m2648.

Karampela, I. and Dalamaga, M. (2020) “Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?,” *Archives of Medical Research*, 51(7), pp. 741–742. doi:10.1016/j.arcmed.2020.06.004.

Kemendes (2020) “Situasi Terkini Perkembangan (COVID-19),” 05 Mei [Preprint]. Available at: https://covid19.kemkes.go.id/download/Situasi_Terkini_050520.pdf.

Kemendes RI (2020) *Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19), Germas*.

Luo, P. *et al.* (2020) “Tocilizumab treatment in COVID-19: A single center experience,” *Journal of Medical Virology*, 92(7), pp. 814–818. doi:10.1002/jmv.25801.

Parasher, A. (2021) “COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment,” *Postgraduate Medical Journal*. BMJ Publishing Group, pp. 312–320. doi:10.1136/postgradmedj-2020-138577.

Patil, V.M., Singhal, S. and Masand, N. (2020) “A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials,” *Life Sciences*. Elsevier Inc. doi:10.1016/j.lfs.2020.117775.

Rangel-Méndez, J.A. and Moo-Puc, R.E. (2020) “N-acetylcysteine as a potential treatment for COVID-19,” *Future Microbiology*. Future Medicine Ltd., pp. 959–962. doi:10.2217/fmb-2020-0074.

Rilinger, J. *et al.* (2020) “A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in

patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial,” *Trials*, 21(1). doi:10.1186/s13063-020-04447-3.

Rothan, H.A. and Byrareddy, S.N. (2020) “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak,” *Journal of Autoimmunity*. Academic Press. doi:10.1016/j.jaut.2020.102433.

Setiadi, A.P. *et al.* (2020) “Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif,” *Indonesian Journal of Clinical Pharmacy*, 9(1), p. 70. doi:10.15416/ijcp.2020.9.1.70.

Seyed Hosseini, E. *et al.* (2020) “The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies,” *Virology*, 551, pp. 1–9. doi:10.1016/j.virol.2020.08.011.

Shakoor, H. *et al.* (2021) “Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?,” *Maturitas*. Elsevier Ireland Ltd, pp. 1–9. doi:10.1016/j.maturitas.2020.08.003.

Shiraki, K. and Daikoku, T. (2020) “Favipiravir, an anti-influenza drug against life-threatening RNA virus infections,” *Pharmacology and Therapeutics* [Preprint]. doi:10.1016/j.pharmthera.2020.107512.

Singh, A.P. *et al.* (2020) “A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation,” *Journal of Clinical Medicine*, 9(6), p. 1867. doi:10.3390/jcm9061867.

Sun, P. *et al.* (2020) “Understanding of COVID-19 based on current evidence,” *Journal of Medical Virology*. John Wiley and Sons Inc., pp. 548–551. doi:10.1002/jmv.25722.

Tavares, L.P., Galvão, I. and Ferrero, M.R. (2021) “Novel Immunomodulatory Therapies for Respiratory Pathologies,” in *Reference Module in Biomedical Sciences*. Elsevier. doi:10.1016/b978-0-12-820472-6.00073-6.

Tobaiqy, M. *et al.* (2020) “Therapeutic management of patients with COVID-19: a systematic review,” *Infection Prevention in Practice*, 2(3), p. 100061. doi:10.1016/j.infpip.2020.100061.

- Wang, M. *et al.* (2020) “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,” *Cell Research*. Springer Nature, pp. 269–271. doi:10.1038/s41422-020-0282-0.
- Wang, Y. *et al.* (2020a) “Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: Study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial,” *Trials*, 21(1), pp. 1–11. doi:10.1186/s13063-020-04352-9.
- Wang, Y. *et al.* (2020b) “Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: Study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial,” *Trials*, 21(1). doi:10.1186/s13063-020-04352-9.
- Ye, X.T. *et al.* (2020) “Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019,” *European Review for Medical and Pharmacological Sciences*, 24(6), pp. 3390–3396. doi:10.26355/eurrev_202003_20706.
- Zhu, N. *et al.* (2020) “A Novel Coronavirus from Patients with Pneumonia in China, 2019,” *New England Journal of Medicine*, 382(8), pp. 727–733. doi:10.1056/nejmoa2001017.